Avastin Safety Questions In Wet AMD Linger With Two-Year CATT Results
Over two years, serious adverse events occurred at a 40% rate for patients treated with Avastin and at a 32% rate for patients receiving Lucentis, CATT researchers report in an article published in the journal Ophthalmology.
You may also be interested in...
Observational cohort data suggest infection risk is lower with off-label use of compounded Avastin than with Genentech's approved ophthalmic treatment, Lucentis, although not statistically significant.
The study’s sponsor, the NIH-funded Diabetic Retinopathy Clinical Research Network, highlighted the cost disparity between treatments for diabetic macular edema in a summary of the study’s purpose.
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.